Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena Corporation plc announced that the US FDA has granted Fast Track designation for PRX012, a potential best-in-class anti-amyloid beta antibody therapy currently being investigated in a Phase I clinical study for the treatment of Alzheimer’s disease.